ScripGilead Sciences’ Yeytuo (lenacapavir) and Eli Lilly’s Kisunla (donanemab) are among the drugs that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended for
Pink SheetThe European Medicines Agency has recommended that Gilead Sciences’ Yeytuo (lenacapavir), for preventing HIV, and 13 other new drugs should be granted pan-EU marketing authorization, but it has advise
Pink SheetThe European Medicines Agency is this week set to decide whether to recommend granting pan-EU marketing authorization for six orphan drugs, including delandistrogene moxeparvovec, Roche/Sarepta Therap
Pink SheetGilead Sciences could learn this week whether the European Medicines Agency will recommend that lenacapavir should be approved for marketing as a twice-yearly preventative option for HIV in the EU as